The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies. The FDA has approved the OncoMate® MSI Dx ...
El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC. Immunotherapy has become a ...
The triplet therapy was effective only in patients with nonmutated PIK3CA and ESR1 genes, achieving a median PFS of 9.1 ...
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...
Significant progress in bispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals has been achieved this year ...
In patients with metastatic breast cancer, pre-treatment interstitial lung abnormalities (ILAs) and human epidermal growth ...
Zelenectide pevedotin (BT8009) demonstrated a well-tolerated safety profile and promising antitumor activity in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback